GlassScriptPhysician profile
Jeffrey Morton Blake
NPI 1477545127
$14,680.02
in general payments reported to CMS, 2019-2025
25 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $290 · 2021: $4,873 · 2022: $1,085 · 2023: $3,272 · 2024: $2,525 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,004 · Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,004.24 |
| Food and Beverage | $2,639.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,311.13 | 2021-2025 | Interstim |
| Axonics, INC. | $2,768.80 | 2023-2024 | Axonics, Bulkamid |
| Allergan, INC. | $2,107.86 | 2019-2021 | |
| Coloplast Corp | $1,963.42 | 2021-2025 | Altis, Restorelle |
| Medtronic USA, INC. | $1,478.09 | 2019-2020 | |
| Stryker Corporation | $672.08 | 2021 | |
| Astellas Pharma US INC | $178.82 | 2019-2025 | Veozah |
| Abbvie INC. | $154.05 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $141.92 | 2023-2025 | |
| Boston Scientific Corporation | $119.82 | 2019-2025 | Axonics |
| Ethicon US, LLC | $103.26 | 2021 | |
| Medline Industries LP | $102.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.46 | 2019 | |
| Sumitomo Pharma America, INC. | $79.58 | 2025 | Gemtesa, Myfembree |
| Vertical Pharmaceuticals, LLC | $62.48 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $54.54 | 2019 | |
| Novo Nordisk INC | $47.65 | 2019-2024 | Wegovy |
| Hologic Sales and Service, LLC | $46.20 | 2024 | Omni Hysteroscope |
| Pfizer INC. | $41.55 | 2019 | |
| Coopersurgical, INC. | $35.69 | 2024-2025 | Endosee |
| Duchesnay USA Incorporated | $31.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2019 | |
| Caldera Medical, INC | $26.66 | 2022 | |
| Valencia Technologies Corporation | $24.36 | 2025 | Ecoin Device Kit |
| Avadel Specialty Pharmaceuticals, LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.